These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 22419670)
1. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670 [TBL] [Abstract][Full Text] [Related]
2. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center. Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455 [TBL] [Abstract][Full Text] [Related]
3. Conventional and advanced magnetic resonance imaging in tumefactive demyelination. Saini J; Chatterjee S; Thomas B; Kesavadas C Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739 [TBL] [Abstract][Full Text] [Related]
4. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Lebrun C; Bensa C; Debouverie M; Wiertlevski S; Brassat D; de Seze J; Rumbach L; Pelletier J; Labauge P; Brochet B; Tourbah A; Clavelou P; Arch Neurol; 2009 Jul; 66(7):841-6. PubMed ID: 19597085 [TBL] [Abstract][Full Text] [Related]
5. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. Dalton CM; Bodini B; Samson RS; Battaglini M; Fisniku LK; Thompson AJ; Ciccarelli O; Miller DH; Chard DT Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451 [TBL] [Abstract][Full Text] [Related]
6. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666 [TBL] [Abstract][Full Text] [Related]
8. [Demyelinating lesions as incidental findings in magnetic resonance imaging: a study of 11 cases with clinico-radiological follow-up and a review of the literature]. Sierra-Marcos A; Mitjana R; Castilló J; Edo MC; Horga-Hernández A; Tintoré M; Río-Izquierdo J; Auger-Acosta C; Rovira A; Montalban X Rev Neurol; 2010 Aug; 51(3):129-34. PubMed ID: 20645263 [TBL] [Abstract][Full Text] [Related]
9. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773 [TBL] [Abstract][Full Text] [Related]